newyorkensis-mediated 7-DHCA levels to suppress secondary BA biosynthesis, which in turn activated hepatic Nfil3-FXR-FGF15 signaling to ameliorate MASLD. The gene discussed is NFIL3; the disease is metabolic dysfunction-associated steatotic liver disease.